7.995 -0.255 (-3.09%) | 02-19 12:48 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 10.53 | 1-year : | 11.44 |
Resists | First : | 9.01 | Second : | 9.8 |
Pivot price | 8.34 ![]() |
|||
Supports | First : | 7.75 | Second : | 6.44 |
MAs | MA(5) : | 8.09 ![]() |
MA(20) : | 8.57 ![]() |
MA(100) : | 9.46 ![]() |
MA(250) : | 9.97 ![]() |
|
MACD | MACD : | -0.3 ![]() |
Signal : | -0.2 ![]() |
%K %D | K(14,3) : | 19.9 ![]() |
D(3) : | 19 ![]() |
RSI | RSI(14): 41.7 ![]() |
|||
52-week | High : | 23.86 | Low : | 3.8 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NVAX ] has closed above bottom band by 23.0%. Bollinger Bands are 50.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 8.55 - 8.59 | 8.59 - 8.62 |
Low: | 8.13 - 8.17 | 8.17 - 8.2 |
Close: | 8.19 - 8.25 | 8.25 - 8.32 |
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Tue, 04 Feb 2025
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Mon, 20 Jan 2025
Novavax, Inc. (NVAX) Stock: The Under-the-Radar Stock Poised for Massive Upside in 2025 - Yahoo Finance
Thu, 09 Jan 2025
Why Novavax Stock Is Volatile This Week - Benzinga
Wed, 08 Jan 2025
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Thu, 12 Dec 2024
Institutional investors control 53% of Novavax, Inc. (NASDAQ:NVAX) and were rewarded last week after stock increased 6.3% - Yahoo Finance
Tue, 10 Dec 2024
Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza - PR Newswire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 160 (M) |
Shares Float | 142 (M) |
Held by Insiders | 8.7 (%) |
Held by Institutions | 60.4 (%) |
Shares Short | 34,940 (K) |
Shares Short P.Month | 36,920 (K) |
EPS | -2.19 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | -3.29 |
Profit Margin | -32.2 % |
Operating Margin | -153.7 % |
Return on Assets (ttm) | -10.8 % |
Return on Equity (ttm) | 0 % |
Qtrly Rev. Growth | -54.8 % |
Gross Profit (p.s.) | 0.72 |
Sales Per Share | 5.52 |
EBITDA (p.s.) | -1.52 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -91 (M) |
Levered Free Cash Flow | -247 (M) |
PE Ratio | -3.68 |
PEG Ratio | 0 |
Price to Book value | -2.44 |
Price to Sales | 1.44 |
Price to Cash Flow | -14.11 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |